Plasma uricase activity and plasma uric acid concentrat | Open-i
Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase | Arthritis Research & Therapy
Immunogenicity of unmodified uricase and PEG-uricases. The development... | Download Scientific Diagram
Uricase Therapy of Gout | Musculoskeletal Key
Emerging Strategies for Effective Management of Treatment-Failure Gout (Slides with Transcript)
Anti-PEG Abs in the clinic 2 . 1 The case of PEG-uricase | Semantic Scholar
In-silico epitope identification and design of Uricase mutein with reduced immunogenicity - ScienceDirect
PEGylation: definition, principles, methods and benefits
PEG Uricase: Long Acting Agent for Treating Gout | Biopharma PEG
Time course of appearance of IgM and IgG antibodies aga | Open-i
Anti-PEG Abs in the clinic 2 . 1 The case of PEG-uricase | Semantic Scholar
A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties | PLOS ONE
![PDF] A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/41089ef858e1e35042f1b1ad8aa3023686e05919/14-Figure9-1.png "PDF] A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties | Semantic Scholar")
PDF] A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties | Semantic Scholar
Hyperuricemia and Gout: New Clinical Insights and Emerging Treatments
Zwitterionic Nanocages Overcome the Efficacy Loss of Biologic Drugs
WO2003011211A2 - Peg-modified uricase - Google Patents
A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties
Free PEGylation (uricase) Icons, Symbols & Images | BioRender
File:PegUricase.png - Wikipedia
